New York Presbyterian Hospital
New York Presbyterian Hospital
News Article | April 21, 2017
Receive press releases from Strathmore Who's Who: By Email Dr. Rubin S. Cooper, of Hollis, New York, has recently been recognized as a Lifetime VIP Member of Strathmores Whos Who for his outstanding contributions and achievements in the field of Pediatric Cardiology. Hollis, NY, April 21, 2017 --( Dr. Rubin Cooper is Chief of Pediatric Cardiology at Cohen Children's Medical Center of New York, as well as Director of the Pediatric Cardiovascular Service Line at the Northwell Health System. He is a Professor of Pediatrics at Hofstra Northwell. Prior to Dr. Cooper’s position at Cohen Children's Medical Center, he was Chief of Pediatric Cardiology at the Komansky Children's Hospital at the New York Presbyterian Hospital, Professor of Clinical Pediatrics at the Weill Cornell Medical College, and Adjunct Professor at the Columbia School of Surgeons and Physicians. While at Cornell he occupied the Starr-Starlight Foundation Chair in Pediatric Cardiology. His clinical research interests include adult congenital heart disease, rheumatic fever, and Kawasaki's Disease; major services include medical education and telehealth. Dr. Cooper is a Board Member of the Make-A-Wish Foundation and has worked with Chai Life Line for close to two decades. He was also a Board Member of the American Heart Association, Long Island Chapter. He is a present Board Member of the Corazon-Corazon Foundation. Dr. Cooper is a Harris Fellow of the International Rotary Gift of Life Foundation. About Strathmore’s Who’s Who Strathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Hollis, NY, April 21, 2017 --( PR.com )-- About Rubin S. CooperDr. Rubin Cooper is Chief of Pediatric Cardiology at Cohen Children's Medical Center of New York, as well as Director of the Pediatric Cardiovascular Service Line at the Northwell Health System. He is a Professor of Pediatrics at Hofstra Northwell. Prior to Dr. Cooper’s position at Cohen Children's Medical Center, he was Chief of Pediatric Cardiology at the Komansky Children's Hospital at the New York Presbyterian Hospital, Professor of Clinical Pediatrics at the Weill Cornell Medical College, and Adjunct Professor at the Columbia School of Surgeons and Physicians. While at Cornell he occupied the Starr-Starlight Foundation Chair in Pediatric Cardiology. His clinical research interests include adult congenital heart disease, rheumatic fever, and Kawasaki's Disease; major services include medical education and telehealth. Dr. Cooper is a Board Member of the Make-A-Wish Foundation and has worked with Chai Life Line for close to two decades. He was also a Board Member of the American Heart Association, Long Island Chapter. He is a present Board Member of the Corazon-Corazon Foundation. Dr. Cooper is a Harris Fellow of the International Rotary Gift of Life Foundation. www.ccmc.northshorelij.com About Strathmore’s Who’s WhoStrathmore's Who's Who publishes an annual two thousand page hard cover biographical registry, honoring successful individuals in the fields of Business, the Arts and Sciences, Law, Engineering and Government. Based on one's position and lifetime of accomplishments, we honor professional men and women in all academic areas and professions. Inclusion is limited to individuals who have demonstrated leadership and achievement in their occupation, industry or profession. Click here to view the list of recent Press Releases from Strathmore Who's Who
News Article | April 18, 2017
The Global Wellness Summit (GWS) today announced that an all-star lineup of integrative medicine leaders will present at the 2017 conference: Dr. Richard Carmona (former U.S. Surgeon General), Elissa Epel, PhD (telomeres research pioneer, UCSF), Dr. Paul Limburg (Professor of Medicine, Mayo Clinic), Dr. Mehmet Oz (Professor of Surgery, Columbia University and host, “The Dr. Oz Show”), Dr. Kenneth R. Pelletier (Professor of Medicine, University of Arizona and UCSF), Dr. Michael Roizen (Chief Wellness Officer, The Cleveland Clinic) and Dr. Andrew Weil (founder, University of Arizona Center for Integrative Medicine and renowned alternative medicine expert). Together, this heavy-hitter roster of experts has transformed the way the world thinks about both wellness and medicine, leading the charge for more holistic, preventive approaches that - as chronic disease and healthcare costs soar - represent one of the most critical trends in the world today. They span celebrity doctors who have brought the “wellness message” to hundreds of millions of people worldwide to doctors who are spearheading a new focus on wellness and prevention at revered medical institutions like the Mayo and Cleveland Clinics. The 2017 Summit theme is “Living a Well Life”, focusing on how new wellness concepts will impact every aspect of an individual’s life. And these leaders, who impact countless individuals’ lives, will keynote on everything from the latest in mind-body medicine and sleep science to the coming wave of personal biomarker and DNA testing. The 11th-annual conference is being held at The Breakers, Palm Beach, Florida from October 9-11, 2017. "The annual Global Wellness Summit has proven to be the premier convener of health and wellness thought leaders from around the world,” said Richard Carmona, MD, MPH, FACS, and 17th Surgeon General of The United States. “This year’s unprecedented meeting in Florida will define the essential role of wellness in a world desperately in need of health innovation and disruption." “This may be the most influential, inspiring and diverse group of medical-wellness pioneers ever assembled on a conference stage,” noted Susie Ellis, GWS CEO and chairman. “And delegates will have the opportunity to interact with them one-on-one during the many networking sessions, lunches and roundtables where casual discussions take place. It will be unprecedented access, something the Summit is known for.” More on the presenters: Richard H. Carmona, MD, M.P.H., FACS, was the 17th Surgeon General of the United States. He is also a combat decorated U.S. Army Special Forces Veteran and a Distinguished Professor at the University of Arizona, with a wide range of training and experience in healthcare management, clinical care and research. He’s currently the Vice Chairman of Canyon Ranch, President of the Canyon Ranch Institute, and serves as Director on several large, publicly traded corporate boards and several private companies. Elissa Epel, PhD, is Professor at the University of California, San Francisco (UCSF), with a research focus on how chronic psychological stress accelerates biological aging; the interconnections between emotions, eating, metabolism and weight; and the effects of mindfulness. A member of the National Academy of Medicine, she has won many awards for her research. Epel co-wrote (with Nobel Laureate, Elizabeth Blackburn) “The Telomere Effect: The New Science of Living Younger Longer”, a 2017 New York Times bestseller. Paul Limburg, MD, M.P.H., is Professor of Medicine, Mayo Clinic College of Medicine and consultant in the division of gastroenterology and hepatology. He also holds a joint appointment in the division of preventive, occupational and aerospace medicine and serves as medical director for several business units at Mayo Clinic responsible for defining or delivering health and wellbeing expertise within and beyond the organization. Mehmet Oz, MD, is Professor of Surgery at Columbia University and has won seven Daytime Emmy® Awards for “The Dr. Oz Show”. He directs the Complementary Medicine Program at New York Presbyterian Hospital; participates in 50 heart surgeries a year; has authored over 400 publications, including seven New York Times bestsellers; has received numerous patents; and hosts the internationally syndicated “Daily Dose” in 134 radio markets and a newspaper column in 175 global markets. He has received numerous global accolades, from being named one of TIME magazine’s “100 Most Influential People” to a Global Leader of Tomorrow by the World Economic Forum. Kenneth R. Pelletier, PhD, MD, is Clinical Professor of Medicine at the University of Arizona and the University of California, San Francisco. At UCSF, he is Director of the Corporate Health Improvement Program (CHIP), a collaborative research program between CHIP and 15 of the Fortune 500. He is Chairman of the American Health Association; medical and business consultant to high-profile organizations like the U.S. Department of Health and Human Services and the World Health Organization; and has published over 300 professional articles on behavioral and integrative medicine, disease management, worksite interventions, and epigenetics. The author of 13 books, his next, “Change Your Genes, Change Your Life”, will be published this year. Michael Roizen, MD: Since 2008, Dr. Roizen has served as Chief Wellness Officer at Cleveland Clinic, the first such position at a major U.S. healthcare institution. He’s also Chairman of the Wellness Institute at Cleveland Clinic; has published 175+ peer-reviewed scientific papers, 100 textbook chapters, and four medical books; received 13 U.S. (and many foreign) patents; and hosted six PBS specials. His “RealAge” and “YOU” series of books have sold millions of copies, have been translated into 44 languages, and resulted in four #1 New York Times bestsellers (more than any other physician). Andrew Weil, MD, is Founder and Director of (and Clinical Professor of Medicine at) the University of Arizona Center for Integrative Medicine, the leading global effort to develop a comprehensive curriculum in integrative medicine. He is editorial director of the popular website, Dr. Weil.com; has appeared in numerous PBS programs; and is founder of the Weil Foundation, Healthy Lifestyle Brands, and True Food Kitchen restaurants. An internationally recognized expert on medicinal plants, alternative medicine, and medical education reform, he’s authored many scientific articles and 15 popular books - and Oxford University Press is currently producing the Weil Integrative Medicine Library, a series for clinicians in various medical specialties. For more information, contact Beth McGroarty: email@example.com or (+1) 213-300-0107. For info on attending the 2017 Summit: http://www.globalwellnesssummit.com/2017-summit/ About the Global Wellness Summit: The Global Wellness Summit (GWS) is an invitation-only international gathering that brings together leaders and visionaries to positively shape the future of the $3.7 trillion global wellness economy. Held in a different location each year, Summits have taken place in the U.S., Switzerland, Turkey, Bali, India, Morocco, Mexico and Austria. The next will be held at The Breakers, Palm Beach, Florida from Oct. 9-11, 2017.
News Article | May 8, 2017
CIOs, CISOs, VPs and Heads of IT from multiple healthcare verticals - including pharmaceuticals, life sciences, hospitals, health insurance organizations, and medical device companies - will gather for an exclusive two-day information-sharing, benchmarking, and networking event. At the Exchange, attendees will explore the latest topics in healthcare mobility, from wearables and security to enterprise apps and IoT. "Mobility is not just desired, but necessary in today's healthcare environment," said Dorene Rettas, Head of Enterprise Mobility Exchange, U.S. "The demand from clinicians and patients to have immediate and secure access to information is being heard loud and clear, yet with HIPAA requirements and compliance laws, it's not an easy task. We've created a meeting format that allows senior-level IT execs to come together to discuss their greatest challenges, address the growing demands placed upon them for mobility, and learn about solutions and support in the market." The Exchange will feature a mix of talented IT thought leaders poised to share their insight and expertise. One such industry expert is Aetna's Director of Software and Mobile Security, Brian Heemsoth, who will speak on the importance of protecting the enterprise while expanding the company's mobile initiatives. New York Presbyterian Hospital's Director of IT Innovation, Shauna Coyne will address how to evolve mobility as the patient's healthcare needs continue to transform, and the importance of digitizing a paper-based organization. In his analyst session titled "Communication is Key," VDC Research Vice President David Krebs will explain how to secure messaging and communications while satisfying governance. These and other presentations will round out an agenda packed with think tanks, round table discussions, networking activities, and meetings with on-site solution providers. Enterprise Mobility Exchange is an online community for business leaders seeking to leverage mobile technology and services to improve operational efficiency, increase customer acquisition, and drive profits. EME's multi-pronged approach provides industry news and expert commentary along with invitation-only events for high-level, global mobility professionals. These events bring together senior IT decision-makers from all industries. Learn more about what's happening in the industry by staying connected with the company's weekly newsletter here. To attend or sponsor Enterprise Mobility Exchange: Healthcare, contact Dorene Rettas at Dorene.Rettas@EnterpriseMobilityExchange.com or by calling +1-973-867-7744.
News Article | May 23, 2017
ATS 2017, WASHINGTON, DC--A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference. Researchers analyzed 3,640,229 patients in the Surveillance, Epidemiology, and End Results (SEER) database and looked at suicide deaths for all cancers and for lung, prostate, breast and colorectal cancers individually. Over a 40 year period, cancer diagnoses were associated with 6,661 suicides. "We wanted to see what the impact of one of life's most stressful events is on patients," said Mohamed Rahouma, MD, a post-doctoral cardiothoracic research fellow at Weill Cornell Medical College/New York Presbyterian Hospital. "I think it's fair to say that most clinicians don't think about suicide risk in cancer patients. This study, I hope, will change that by making us more aware of those at greatest risk of suicide so that this catastrophe in the care of our patients doesn't happen." Among lung cancer patients, Asians have a more than 13-fold and men a nearly 9-fold increase in suicides. Other factors that increased suicide risk were being older, being widowed, refusing surgical treatment and having a difficult-to-treat (metastatic) type of lung cancer. The authors noted that over the 40-year study period, suicide rates decreased, most notably for lung cancer when compared to the other three most common cancers. "While cancer diagnosis counselling is an established practice, especially if a patient seems depressed, referral for ongoing psychological support and counseling typically does not happen," Dr. Rahouma said. "This represents a lost opportunity to help patients with a devastating diagnosis." Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population based analysis. Authors: M. Rahouma, M. Kamel, A. Nasar, S. Harrison, B. Lee, B. Stiles, N. Altorki, J.L. Port; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY - New York, NY/US Previous studies have reported that the psychological and social distresses associated with cancer diagnosis have led to an increase in suicides compared to the general population. In the current study we sought to explore lung cancer associated suicide rates in a large national database compared to the general population as well as to the three most prevalent non-skin cancers [breast, prostate, colorectal cancer (CRC)]. The Surveillance, Epidemiology, and End Results (SEER) database (1973-2013) was retrospectively queried to identify cancer associated suicide deaths in all cancers combined, as well as, for each of lung, prostate, breast, or colorectal cancers. Suicide incidence and standardized mortality ratio (SMR) were estimated by using SEER*Stat 8.3.2 program. Suicidal rate for the general US population was obtained from National Vital Statistics Reports, Vol.64, No. 2. Furthermore, suicidal trends over time and timing from cancer diagnosis to suicide were estimated for each cancer type. Among lung cancer patients, suicide SMR of different demographic, social and tumor related factors were identified. Among 3,640,229 patients diagnosed with cancer in the study period, 6661 patients committed suicide. The cancer associated suicide rate was 27.5/100,000 person-years (SMR=1.6) compared to 13 /100,000 person-years for the general US population. The highest suicide risk was observed in lung cancer patients (SMR= 4.2) followed by CRC (SMR=1.4), breast cancer (SMR=1.4) and prostate cancer (SMR=1.2). Median time to suicide was 7 months from diagnosis in lung cancer, 56 months in prostate ca, 52 months in breast cancer and 37 months in CRC (p There was a trend towards the decrease in suicide SMR over time, which is most notable for lung cancer compared to the other three cancers (Figure). Among lung cancer patients; suicide SMR was higher in males (SMR=8.8), Asians (SMR=13.7), widowed patients (SMR=11.6), older patients (70-75 years; SMR=12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR=11.2), patients presenting with metastatic disease (SMR=13.9) and in patients who refused to receive surgical treatment (SMR=13). The cancer associated suicide rate is nearly twice that of US-general population. Suicide risk is highest among lung cancer patients, particularly older patients, widowed, males, and patients with unfavorable tumor characteristics. It is important to identify these high risk patients in order to provide the proper psychological assessment, support, and counselling to reduce these rates.
News Article | May 23, 2017
Dr. Bryan T. Kelly, Chief of Sports Medicine Service, Hospital for Special Surgery, has joined The Expert Network©, an invitation-only service for distinguished professionals. Dr. Kelly has been chosen as a Distinguished Doctor™ based on peer reviews and ratings, numerous recognitions, and accomplishments achieved throughout his career. Dr. Kelly outshines others in his field due to his extensive educational background, in-depth medical expertise, and career longevity. He earned his Bachelor’s degree from Brown University in Providence, Rhode Island. With his sights set on sports medicine, he enrolled in medical school at Duke University. He completed his internship in general medicine at the New York Presbyterian Hospital and his residency in orthopedic surgery at the Hospital for Special Surgery. Committed to achieving the most comprehensive education possible, Dr. Kelly went on to complete a number of fellowships. He spent two years at the Hospital for Special Surgery specializing in sports medicine and shoulder surgery. Dr. Kelly also studied hip sports injuries and arthroscopy under Dr. Marc J. Philippon, M.D., during his fellowship at the University of Pittsburgh Medical Center. Before starting his practice, he went abroad to complete fellowships with Dr. Herbert Resch at the Landeskliniken Hospital in Salzburg, Austria, and with Professor Reinhold Ganz in Bern, Switzerland, studying advanced techniques in open management of hip and shoulder injuries. With 14 years dedicated to medicine, Dr. Kelly brings a wealth of knowledge to his industry and, in particular, to his area of expertise, sports medicine with a subspecialty in hip injuries. When asked why he decided to pursue a career in medicine, Dr. Kelly said: "Initially I was a music major, but I was very interested in athletics and sports medicine. That is what drove my decision to go to medical school—I knew from the get-go that it was going to be orthopedic surgery." As a thought-leader in his specialty, Dr. Kelly has authored over one hundred and fifty scientific publications, chapters, review articles, and books on various topics of hip injuries, diagnoses, and treatments. He hosts a broad range of both clinical and basic science research interests, including the development of clinical outcomes registry and the development of novel surgical techniques for managing soft tissue injuries around the hip joint, among others. He is currently investigating non-arthritic hip pain in athletes and working on the use of novel biomaterials for synthetic meniscal replacement in the knee. Kelly was also the recipient of a grant from the National Institutes of Health in 2014 to study the comparative effectiveness of femoroacetabular impingement arthroscopy. He is dedicated to imparting his knowledge onto others, serving as Professor of Orthopedic Surgery and Associate Professor of Orthopedic Surgery-Academic track at New York Presbyterian Weill Cornell Medical College. With such prominence in his field, Dr. Kelly is sure to keep himself abreast of prevailing trends within orthopedic surgery: "My specialty is relatively new, so the understanding of specific injuries in the athletic population has developed a lot over the last ten to fifteen years. Sports medicine is my area of expertise so I am currently paying attention to developments in that arena." For more information, visit Dr. Kelly's profile on the Expert Network here: https://expertnetwork.co/members/bryan-kelly/3a40838a3dd4bf7a The Expert Network© has written this news release with approval and/or contributions from Dr. Bryan T. Kelly. The Expert Network© is an invitation-only reputation management service that is dedicated to helping professionals stand out, network, and gain a competitive edge. The Expert Network selects a limited number of professionals based on their individual recognitions and history of personal excellence.
News Article | May 24, 2017
NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that Ronald O. Perelman and Dr. Anna Chapman, through the Perelman Family Foundation, have committed more than $4 million in funding to launch the first ever research program solely dedicated to the early detection and prevention of multiple myeloma. This generous donation will seed the launch of the groundbreaking Perelman Family Foundation Early Disease Translational Research Program, part of the MMRF Prevention Project, to speed efforts toward early detection, delayed disease progression, and eventually, ultimately, prevention of this incurable disease. “The goal of this initiative is to develop a completely new paradigm for research in multiple myeloma, focusing on early detection and ultimately, prevention. Right now, detection of this terrible disease often comes too late. Unlike most cancers, early detection of multiple myeloma doesn't increase a person’s chance of survival under current treatment options. The Perelman Family Foundation Early Disease Translational Research Program will support research focused on improving outcomes after early detection. With the MMRF and our university partners, we are confident that we will be able to make breakthroughs for multiple myeloma patients, and that the program will serve as a model for future initiatives,” said Dr. Anna Chapman. The gift from the Perelman Family Foundation provides a catalyst for essential research focused on: better understanding genomic determinants of early disease progression; how microenvironment factors influence early disease progression; and enhancing patient tumor immunity. Perelman Family Foundation Early Disease Translational Research Program brings together six leading cancer research centers: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Rockefeller University, University of Arkansas for Medical Science, Yale University, as well as the MMRF. The studies conducted by these teams will identify novel targets and biomarkers of disease progression and enable the development of therapeutic approaches to delay or even stop progression to myeloma. “We are so thankful to Ronald and Anna for supporting our vision for a bold program that will take us one step closer to a future where our children and grandchildren will never need to worry about incurable cancers,” said the Multiple Myeloma Research Foundation Founder Kathy Giusti. “Not only does the MMRF answer the questions of patients today and urgently deliver them the precise information and treatment they need to fight their multiple myeloma, but, with this generous donation, we will now also be able to focus on the patients of tomorrow.” Inspired by the dedication and vision of its Chairman and CEO Ronald O. Perelman and his family, the Perelman Family Foundation is firmly committed to philanthropy, focusing on women’s health, education and the arts. Ranked among the top philanthropists in the United States, Mr. Perelman is the founder of the Revlon/UCLA Women’s Cancer Research Program, which analyzes the causes of and develops groundbreaking treatment for breast and ovarian cancer. Launched in 1994, the program was responsible for the development of Herceptin, the first genetically-based treatment for a major cancer to be approved by the FDA, which currently cures more than thirty percent of breast cancer cases in women. In 2014, he co-founded, along with Barbra Streisand, the Women’s Heart Alliance to raise awareness, encourage action and drive new research to fight heart disease in women. Through the Perelman Family Foundation, Mr. Perelman supports the Ronald O. Perelman Center for Emergency Services and the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center; the Ronald O. Perelman Heart Institute at New York Presbyterian Hospital, an internationally-recognized center offering comprehensive, innovative, and world-class cardiovascular care and heart health education; and the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medicine. Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,280 adults will be diagnosed this year and 12,590 people are predicted to die from the disease. The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentless pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501 (c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $350 million and directs nearly 90% of the total funds to research and related programs. As a result, the MMRF has been awarded by Charity Navigator’s coveted four-star rating for 12 years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.
News Article | May 11, 2017
There are an estimated three million cholera cases per year around the world and more than 8 million U.S. travelers per year going to countries where cholera occurs. More than 80 percent of reported U.S. cases are associated with travel to cholera-endemic countries in Africa, Asia and the Caribbean.1 Of the top 20 international destinations of U.S. travelers; five are to cholera-endemic countries, including the Dominican Republic, Jamaica, China, India and the Philippines. Additionally, in recent years, there has been a rapid spread and re-emergence of cholera in the Americas, with cases reported in Cuba, Mexico, Ecuador and Haiti. Despite this, cholera remains underreported. "Cholera has shown itself to be an emerging pathogen in the Western hemisphere," said Bradley A. Connor, M.D., Clinical Professor of Medicine at the Weill Cornell Medical College, Attending Physician at the New York Presbyterian Hospital-Cornell Campus and Medical Director, The New York Center for Travel and Tropical Medicine. "The recent outbreak in Haiti demonstrated that cholera can evolve to become an even larger issue in areas we haven't seen before. These new CDC guidelines will help educate healthcare providers who see travelers to consider vaccination for those who may be at risk for contracting cholera." Vaxchora, a single-dose vaccine, was approved by the U.S. Food and Drug Administration (FDA) in June 2016 for active immunization against disease caused by Vibrio cholerae serogroup O1. The approval was based on positive results from a 10-and 90-day cholera challenge trial that demonstrated vaccine efficacy of 90.3% at 10 days and 79.5% at three months post-vaccination, as well as two safety and immunogenicity trials in healthy adults. Cholera, transmitted by ingestion of food and water contaminated with Vibrio cholerae, is an important cause of diarrhea that may be severe and life-threatening in some individuals. If untreated, death may result in 24 hours.1 A recent report from the CDC suggests that the true number of cholera cases in the U.S. is at least 30 times higher than observed by national surveillance systems.3 Non-vaccine intervention to prevent cholera infection is the avoidance of contaminated water and food, but studies have shown that 98 percent of travelers do not comply with these precautions when traveling.4 Vaxchora is an oral vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. Vaxchora is approved for use in adults 18 through 64 years of age traveling to cholera-affected areas. The effectiveness of Vaxchora has not been established in persons living in cholera-affected areas or in persons who have pre-existing immunity due to previous exposure to Vibrio cholerae or receipt of a cholera vaccine. Vaxchora has not been shown to protect against disease caused by Vibrio cholerae serogroup O139 or other non-O1 serogroups. Vaxchora is contraindicated in people with a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of Vaxchora or to a previous dose of any cholera vaccine. The safety and effectiveness of Vaxchora have not been established in immunocompromised persons. Vaxchora may be shed in the stool of recipients for at least seven days. There is a potential for transmission of the vaccine strain to non-vaccinated close contacts (e.g., household contacts). Use caution when considering whether to administer Vaxchora to individuals with immunocompromised close contacts. The most common adverse reactions (incidence >3%) were: tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%) and diarrhea (4%). For the full Prescribing Information, please visit www.vaxchora.com. PaxVax is a leading independent vaccine company that is devoted to bringing specialty vaccines that protect against overlooked infectious diseases to market, providing effective tools for health care providers who serve the 100 million people per year who travel to countries where these diseases are present. It commercializes vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora™), and has a robust pipeline with vaccines at various stages of preclinical and clinical development for adenovirus, chikungunya, hepatitis A, HIV and Zika. As part of its social mission, PaxVax is also committed to making its vaccines available for use in developing world and increasing access to vaccines for the people who need them most. More information is available at http://www.paxvax.com/. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cdc-recommends-that-adults-traveling-to-cholera-affected-destinations-get-vaccinated-with-vaxchora-cholera-vaccine-live-oral-300456352.html